Cargando…
Angiotensin Converting Enzyme Inhibitor and HMG-CoA Reductase Inhibitor as Adjunct Treatment for Persons with HIV Infection: A Feasibility Randomized Trial
BACKGROUND: Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed. DESIGN AND METHODS: We conducted a 2×2 factorial feasibility study of lisinopril (L) (10 mg daily) vs L-placebo in c...
Autores principales: | Baker, Jason V., Huppler Hullsiek, Kathleen, Prosser, Rachel, Duprez, Daniel, Grimm, Richard, Tracy, Russell P., Rhame, Frank, Henry, Keith, Neaton, James D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474775/ https://www.ncbi.nlm.nih.gov/pubmed/23082133 http://dx.doi.org/10.1371/journal.pone.0046894 |
Ejemplares similares
-
Predictive Modeling
of HMG-CoA Reductase Inhibitory
Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023) -
Pleiotropic effects of the HMG-CoA reductase inhibitors
por: Mihos, Christos G, et al.
Publicado: (2011) -
Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo
por: Noël, Martin, et al.
Publicado: (2004) -
Synergistic effects of HMG‐CoA reductase inhibitor and angiotensin II receptor blocker on load‐induced heart failure
por: Ito, Yusuke, et al.
Publicado: (2018) -
Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer
por: Solanki, Abhishek A, et al.
Publicado: (2011)